Thompson Davis & CO. Inc. Has $581,000 Stake in Profound Medical Corp. (NASDAQ:PROF)

Thompson Davis & CO. Inc. trimmed its stake in Profound Medical Corp. (NASDAQ:PROF) by 20.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 68,425 shares of the company’s stock after selling 17,950 shares during the quarter. Profound Medical comprises 0.5% of Thompson Davis & CO. Inc.’s portfolio, making the stock its 23rd largest holding. Thompson Davis & CO. Inc.’s holdings in Profound Medical were worth $581,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in PROF. Raymond James Financial Services Advisors Inc. lifted its position in Profound Medical by 13.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 622,552 shares of the company’s stock worth $5,285,000 after buying an additional 71,845 shares in the last quarter. Zweig DiMenna Associates LLC increased its stake in shares of Profound Medical by 49.7% in the fourth quarter. Zweig DiMenna Associates LLC now owns 130,617 shares of the company’s stock worth $1,109,000 after acquiring an additional 43,343 shares during the last quarter. Raymond James & Associates raised its holdings in shares of Profound Medical by 8.2% during the third quarter. Raymond James & Associates now owns 67,731 shares of the company’s stock worth $691,000 after acquiring an additional 5,125 shares in the last quarter. Finally, MTM Investment Management LLC boosted its position in Profound Medical by 8.2% during the third quarter. MTM Investment Management LLC now owns 19,875 shares of the company’s stock valued at $203,000 after purchasing an additional 1,500 shares during the last quarter. 47.86% of the stock is currently owned by institutional investors and hedge funds.

Profound Medical Stock Down 3.4 %

NASDAQ PROF traded down $0.26 during trading on Tuesday, reaching $7.44. The company’s stock had a trading volume of 17,644 shares, compared to its average volume of 40,266. The company has a current ratio of 6.58, a quick ratio of 5.48 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $181.76 million, a PE ratio of -5.51 and a beta of 0.80. The business has a 50-day moving average price of $8.26 and a 200-day moving average price of $8.73. Profound Medical Corp. has a 1-year low of $7.11 and a 1-year high of $15.49.

Profound Medical (NASDAQ:PROF) last posted its earnings results on Thursday, March 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). The business had revenue of $2.01 million during the quarter, compared to analyst estimates of $1.90 million. Profound Medical had a negative net margin of 396.85% and a negative return on equity of 70.18%. On average, research analysts forecast that Profound Medical Corp. will post -1.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners cut their price target on Profound Medical from $14.25 to $12.75 and set a “buy” rating for the company in a research note on Thursday, January 4th.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.